ℹ️
🇬🇧
Search
Search for publications relevant for "phase III study"
phase III study
Publication
Class
Person
Publication
Programmes
publication
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma
2021 |
Faculty of Medicine in Hradec Králové, Central Library of Charles University
publication
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial
2007 |
Faculty of Medicine in Pilsen
publication
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial
2007 |
First Faculty of Medicine, Faculty of Medicine in Pilsen
publication
Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study
2017 |
Second Faculty of Medicine
publication
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study
2021 |
Second Faculty of Medicine
publication
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
2022 |
Faculty of Medicine in Hradec Králové
publication
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
2019 |
First Faculty of Medicine
publication
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
2017 |
Faculty of Medicine in Hradec Králové
publication
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma
2019 |
First Faculty of Medicine
publication
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)
2021 |
First Faculty of Medicine
publication
Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations : Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies
2015 |
First Faculty of Medicine
publication
Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study
2022 |
First Faculty of Medicine
publication
Long-term efficacy and safety adalimumab in children with juvenile rheumatoid arthritis (JRA): converting from body-surface-area dosing to weight-based fixed dosing in the open-label extension (OLE) of a phase III study
Publication without faculty affiliation
publication
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
+1
2009 |
Publication without faculty affiliation
publication
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study
2018 |
Publication without faculty affiliation
publication
Pharmacokinetics, efficacy and safety of IMMUNATE (R) Solvent/Detergent (IMMUNATE (R) S/D) in previously treated patients with severe hemophilia A: Results of a prospective, multicenter, open-label phase III study
2008 |
Second Faculty of Medicine
publication
Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study
2020 |
Faculty of Medicine in Pilsen
publication
A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA
2020 |
First Faculty of Medicine
publication
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression
2007 |
First Faculty of Medicine
publication
Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer
2008 |
Third Faculty of Medicine
publication
A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease
2010 |
Third Faculty of Medicine
publication
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study
2019 |
Publication without faculty affiliation
publication
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
2017 |
First Faculty of Medicine
publication
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
2016 |
First Faculty of Medicine
publication
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression(aEuro)
2016 |
Publication without faculty affiliation
publication
Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-0897113; Silva Study)
2005 |
Third Faculty of Medicine
publication
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients
2017 |
Publication without faculty affiliation
publication
Efficacy and safety of exenatide as add-on therapy for patients with type 2 diabetes with an intensive insulin regimen : A randomized double-blind trial
2021 |
Faculty of Medicine in Pilsen
publication
Comment to study: A randomized phase |III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild type (WT) KRAS metastatic colorectal cancer (mCRC) patients: German study AIO KRK-0306(FIRE-3)
2013 |
First Faculty of Medicine